Relief of Discomfort

Silent Nights Research

Studies Summary:

What is the Silent Nights Patch?

Based on the clinical research, the LifeWave Silent Nights patch is a non-transdermal, Class I biomodulation device designed to improve sleep without introducing any chemicals or drugs into the body. When placed on specific acupuncture points, the patch uses natural body heat to activate organic nanoscale crystals, which act as passive reflectors that send specific infrared wavelengths back into the skin to support natural sleep regulation.


Key Findings & What They Mean

  • Neurochemical Support for Natural Sleep: Clinical trials showed that nightly use of the patch produced a statistically significant increase in serotonin levels within 7 days. Because serotonin is the direct precursor to melatonin, this shift supported natural sleep cycles, including an age-stratified 202% increase in melatonin production for individuals under 30.

  • Measurable Improvements in Sleep Architecture: Wrist actigraphy tracking demonstrated that patch use led to a 29% reduction in nighttime movement, a 22% reduction in total awake time, a 28% drop in restlessness, and a 66% overall increase in sleep duration (adding an average of 2.22 to 2.53 hours of sleep per night).

  • High Subjective Satisfaction & Daytime Alertness: Clinical evaluation scales reported that 80% to 88% of participants experienced significant improvements in overall sleep quality and length, with 72% maintaining normal daytime alertness without any drug-like "hangover" effects.

  • Calming the Nervous System & Restoring Cellular Function: Heart rate variability (HRV) and thermal imaging revealed a helpful decrease in "fight-or-flight" sympathetic stress drive, accompanied by localized skin cooling (-8.5°F). Furthermore, Electro Interstitial Scanning (EIS) confirmed cellular functional restoration across key brain structures (like the hypothalamus and hippocampus), the heart, adrenals, and thyroid.

  • Safe, Drug-Free Alternative: Across the controlled trials, the patch provided a safe, non-invasive alternative to conventional sleep medications—restoring deep sleep through natural autonomic and neurochemical balancing with zero reported adverse side effects or dependency risks.

Clinical Studies:

Trial 1: Treatment of Insomnia with Energetic Acupuncture Point Activation: A Double-Blind Placebo Randomized Trial

  • Source File(s): Treatment-of-Insomnia-with-Energetic-Acupuncture-Point-Activation-A-Double-Blind-Placebo-Randomized-Trial.pdf and Study Report #3 in Treatment Of Insomnia With Nontransdermal Acupuncture Point Activation (A Pilot Study).pdf.

  • Study Title: Treatment of Insomnia with Energetic Acupuncture Point Activation: A Double-Blind Placebo Randomized Trial.

  • Study Type / Design: Double-blind, randomized, placebo-controlled trial (Phase 1: 2-week double-blind active vs. placebo) followed by a 4-week open-label extension phase (Phase 2: all subjects received active patches).

  • Sample Size & Demographics: 50 enrolled subjects suffering from chronic insomnia of at least 3 months duration with baseline sleep averaging less than 6 hours per night (31 females, 19 males; age range 18–80 years; 46 completed protocol—23 active, 23 placebo; 4 dropouts).

  • Intervention / Testing Period: Daily cutaneous application of non-transdermal Silent Nights patches at bedtime over 6 weeks total. Phase 1 (Days 0–14): 23 active vs. 23 placebo. Phase 2 (Days 14–42): All 46 subjects received active patches for 4 additional weeks. Patches were rotated across 5 acupuncture points: Right Liver 3, Right Triple Heater 23, Right Triple Heater 17, Governing Vessel 24.5, or Right Stomach 36. Active and placebo patches were stored in separate Faraday cages to prevent energetic interchange.

  • Key Metrics Measured: Sleep Analog Scale (primary outcome tracking self-reported nightly sleep duration in hours), Pittsburgh Sleep Quality Index (PSQI), Leeds Sleep Evaluation Questionnaire (LSEQ), Epworth Sleepiness Scale (ESS), Total Symptom Index, and Adverse Event safety monitoring.

  • Primary Results & Findings:

    • Phase 1 (2-Week Double-Blind Phase): Active patch wearers increased sleep duration by 2.22 ± 0.41 hours per night (from 3.93 to 6.15 hours), whereas the placebo group increased by 0.98 ± 0.45 hours per night (from 3.76 to 4.74 hours). The active patch group achieved a statistically significant 1.24-hour net increase in sleep duration over placebo (\(p = 0.048\)).

    • Phase 2 (6-Week Total Study): After 4 additional weeks of active patch wear, average nightly sleep duration across all 46 participants increased by 2.53 ± 0.29 hours per night (\(p < 0.001\)), representing a 66% overall increase in sleep duration over baseline.

    • Safety: Zero adverse reactions occurred during the 6-week trial, confirming excellent patch tolerance.

Treatment of Insomnia with Energetic Acupuncture Point Activation: A Double-Blind Placebo Randomized Trial.pdf





Trial 2: The Effects of LifeWave Silent Nights Patches on Sleep (30-Day Open-Label Pilot Study)

  • Source File(s): The Effects of LifeWave Silent Nights Patches on Sleep.pdf and Study Report #1 in Treatment Of Insomnia With Nontransdermal Acupuncture Point Activation (A Pilot Study).pdf.

  • Study Title: The Effects of LifeWave Silent Nights® Patches on Sleep / Treatment of Insomnia with Nontransdermal Acupuncture Point Activation (A Pilot Study).

  • Study Type / Design: Open-label, single-arm clinical pilot study.

  • Sample Size & Demographics: 25 adult participants suffering from chronic insomnia (age range 18 to 80 years; 24 completed, 1 dropped out).

  • Intervention / Testing Period: Non-transdermal Silent Nights patch applied daily at bedtime over 30 days (worn 5 nights per week). Patches rotated across 5 acupuncture points (Right Liver 3, Right Triple Heater 23, Right Triple Heater 17, Governing Vessel 24.5, or Right Stomach 36) until participants established their optimal point.

  • Key Metrics Measured: Pittsburgh Sleep Quality Index (PSQI), Leeds Sleep Evaluation Questionnaire (LSEQ), Epworth Sleepiness Scale (ESS), Sleep Analog Scale, Zung Test for Depression, Total Life Stress Test, and Symptom Index.

  • Primary Results & Findings:

    • 88% of participants (22 of 25) demonstrated improved length of sleep on the PSQI and Sleep Analog Scale.

    • 80% of participants (20 of 25) achieved improved quality of sleep on the Leeds Sleep Evaluation Questionnaire (LSEQ score \(\le 28\) reduced from 16 to 5 subjects).

    • 72% of participants maintained normal daytime sleepiness levels on the Epworth Sleepiness Scale (ESS score \(\le 10\)).

    • Secondary psychological metrics (Zung depression and Total Life Stress) showed less change relative to direct sleep outcomes. Zero adverse events were reported.

The Effects of LifeWave Silent Nights Patches on Sleep (30-Day Open-Label Pilot Study).pdf

Trial 3: Silent Nights Patch Improves Qualitative and Quantitative Measures of Sleep and Enhances Quantitative Markers of Organ Function

  • Source File(s): Study Report #2 in Treatment Of Insomnia With Nontransdermal Acupuncture Point Activation (A Pilot Study).pdf.

  • Study Title: Silent Nights® Patch Improves Qualitative and Quantitative Measures of Sleep and Enhances Quantitative Markers of Organ Function.

  • Study Type / Design: Controlled 3-week longitudinal clinical trial (1-week baseline accommodation followed by 2 weeks of nightly patch application).

  • Sample Size & Demographics: 20 adult volunteers (5 males, 15 females; age range 20–79 years).

  • Intervention / Testing Period: Baseline data collected over 1 week while subjects accommodated to wearing wrist Actiwatches. Silent Nights patches were then worn nightly on the right temple (Triple Warmer 23/22) and right ankle (Liver 3 / Kidney 3) 1 hour before sleep for 2 consecutive weeks.

  • Key Metrics Measured: Actigraphic movement recording during sleep (wrist Actiwatch), Electro Interstitial Scanning (EIS bioelectrical impedance measuring cellular physiologic status across 10 internal organs/brain regions), Leeds Sleep Evaluation Questionnaire (LSEQ), and subjective daily sleep logs. Organs evaluated included the frontal lobe, temporal lobe, hippocampus, hypothalamus, pituitary gland, thyroid gland, kidneys, adrenal glands, liver, small intestine, large intestine, and cardiac ventricles.

  • Primary Results & Findings:

    • Actigraphy Objective Movement Gains: Wearing the patch for 2 weeks produced a 29% reduction in movement activity during sleep, a 22% reduction in total awake time, a 28% increase in the ratio of time in bed versus awake time, and a 28% reduction in nocturnal restlessness.

    • Qualitative Sleep Improvements: LSEQ and sleep diary data showed marked improvements in getting to sleep easier and quicker, calmer sleep with fewer wakeful periods, easier morning awakening, enhanced daytime alertness, and less disrupted physical balance and coordination upon waking.

    • EIS Cellular Organ Function Restoration: Statistical analysis of EIS bio-impedance data demonstrated statistically significant improvements in cellular physiologic functional status across key brain structures (frontal lobe, temporal lobe, hippocampus, hypothalamus), cardiac ventricles, adrenal glands, and thyroid gland compared to baseline. Zero adverse events occurred.

Silent Nights Patch Improves Qualitative and Quantitative Measures of Sleep and Enhances Quantitative Markers of Organ Function.pdf





Trial 4: Hormonal, Amino Acid, Neurotransmitter, GDV and Physiological Testing of the LifeWave Silent Nights Patches

  • Source File(s): Hormonal, Amino Acid, Neurotransmitter, GDV and Physiological Testing of the LifeWave Silent Nights Patches.pdf.

  • Study Title: Hormonal, Amino Acid, Neurotransmitter, GDV and Physiological Testing of the LifeWave Silent Nights Patches.

  • Study Type / Design: Single-arm, longitudinal pilot study (uncontrolled convenience sample).

  • Sample Size & Demographics: 5 healthy adult participants (aged 21 and older, spanning younger adults under 30 to older adults over 65).

  • Intervention / Testing Period: Active Silent Nights patch worn nightly at bedtime (placed at acupuncture point CV6 for a minimum of 8 hours/night) for 6 consecutive nights, evaluated over 7 days (Baseline Day 1, Day 2, Day 6, and Day 7).

  • Key Metrics Measured: Salivary neurotransmitters and amino acids (Melatonin, Serotonin, Dopamine, Norepinephrine, Epinephrine, GABA, Glutamate, Histamine, Theanine, L-DOPA, etc.); salivary hormones (Cortisol, DHEA, Estrogen, Progesterone, Testosterone); Gas Discharge Visualization (GDV biophoton emission and fingertip fractality analysis); Thought Technology ProCom Infiniti HRV/EMG suite (dermal skin temperature, heart rate variability); and standardized psychological questionnaires (POMS, Global Mood Scale, Leeds, Marlowe-Crowne, Tellegen Absorption, Hassles and Uplifts, sVAS for sleep).

  • Primary Results & Findings:

    • Serotonin Precursor Activation: Serotonin increased significantly across all 5 subjects at all timepoints over 7 days (Day 6 \(p = 0.0030\), Day 7 \(p = 0.0097\)). Serotonin is the direct metabolic precursor required for endogenous melatonin synthesis.

    • Age-Stratified Melatonin Surge: While overall group melatonin did not reach statistical significance due to age-related baseline decline in subjects over 65, participants under age 30 achieved a 202% increase in blood/urinary melatonin levels over 7 days.

    • HRV Skin Temperature Reduction: Statistically significant reductions in skin temperature occurred from Day 1 to Day 4 (Epoch 1 \(-8.5 \pm 4.43^\circ\text{F}, p = 0.0313\); Epoch 2 \(-8.82 \pm 5.45^\circ\text{F}, p = 0.0479\)), indicating an overall downregulation of sympathetic stress tone.

    • GDV Biofield & Polyvagal Response: Statistically significant decrease in fractality dimension at Day 6 (Left 3 finger, \(p = 0.0376\)), supporting stress reduction across the hypothalamus and thoracic polyvagal system.

    • Mood & Affect Improvement: Statistically significant reduction in negative affect on the Global Mood Scale at Day 5 (\(p = 0.0373\)) and significant reductions in POMS total mood disturbance scores at Day 6 (\(-9.2 \pm 4.02, p = 0.0069\)) and Day 7 (\(-12.6 \pm 2.61, p = 0.0004\)).

Hormonal, Amino Acid, Neurotransmitter, GDV and Physiological Testing of the LifeWave Silent Nights Patches.pdf